JP2022525476A - 腫瘍選択的併用療法 - Google Patents

腫瘍選択的併用療法 Download PDF

Info

Publication number
JP2022525476A
JP2022525476A JP2021556462A JP2021556462A JP2022525476A JP 2022525476 A JP2022525476 A JP 2022525476A JP 2021556462 A JP2021556462 A JP 2021556462A JP 2021556462 A JP2021556462 A JP 2021556462A JP 2022525476 A JP2022525476 A JP 2022525476A
Authority
JP
Japan
Prior art keywords
tumor
nqo1
cells
lap
dnq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021556462A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020190990A5 (https=
JP2022525476A5 (https=
Inventor
ヤン－シン フー
シュウメイ ホアン
デイヴィッド ブースマン
ポール ジェイ． ハーゲンロザー
シャオグワン リ
リンシャン ジャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Illinois
University of Texas System
Original Assignee
University of Texas System
University of Illinois System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Illinois System filed Critical University of Texas System
Publication of JP2022525476A publication Critical patent/JP2022525476A/ja
Publication of JPWO2020190990A5 publication Critical patent/JPWO2020190990A5/ja
Publication of JP2022525476A5 publication Critical patent/JP2022525476A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2021556462A 2019-03-18 2020-03-18 腫瘍選択的併用療法 Pending JP2022525476A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962819870P 2019-03-18 2019-03-18
US62/819,870 2019-03-18
PCT/US2020/023250 WO2020190990A1 (en) 2019-03-18 2020-03-18 Tumor-selective combination therapy

Publications (3)

Publication Number Publication Date
JP2022525476A true JP2022525476A (ja) 2022-05-16
JPWO2020190990A5 JPWO2020190990A5 (https=) 2023-03-23
JP2022525476A5 JP2022525476A5 (https=) 2023-03-23

Family

ID=72519160

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556462A Pending JP2022525476A (ja) 2019-03-18 2020-03-18 腫瘍選択的併用療法

Country Status (10)

Country Link
US (1) US20220160703A1 (https=)
EP (1) EP3942061A4 (https=)
JP (1) JP2022525476A (https=)
KR (1) KR20220004025A (https=)
CN (1) CN113905763A (https=)
AU (1) AU2020240035A1 (https=)
BR (1) BR112021018545A2 (https=)
CA (1) CA3130513A1 (https=)
MX (1) MX2021011301A (https=)
WO (1) WO2020190990A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230128175A (ko) * 2022-02-25 2023-09-04 주식회사 온코크로스 루복시스타우린을 포함하는 항암용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040492A1 (en) * 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Methods of treating cancer comprising targeting nqo1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2909091C (en) * 2013-04-09 2021-11-02 The Board Of Trustees Of The University Of Illinois Tumor-selective combination therapy
WO2017025496A1 (en) * 2015-08-12 2017-02-16 Bayer Pharma Aktiengesellschaft Pharmaceutical combination for the treatment of cancer
SG11201808306PA (en) * 2016-03-24 2018-10-30 Tragara Pharmaceuticals Inc Treatment of cancer with tg02
KR102922386B1 (ko) * 2017-07-21 2026-02-04 제넨테크, 인크. 암에 대한 치료 및 진단 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012040492A1 (en) * 2010-09-22 2012-03-29 The Board Of Regents Of The University Of Texas System Methods of treating cancer comprising targeting nqo1

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
J.AM.CHEM.SOC., vol. 132, JPN6018000175, 2010, pages 5469 - 5478, ISSN: 0005270088 *

Also Published As

Publication number Publication date
BR112021018545A2 (pt) 2021-12-14
CN113905763A (zh) 2022-01-07
EP3942061A1 (en) 2022-01-26
CA3130513A1 (en) 2020-09-24
MX2021011301A (es) 2022-01-19
EP3942061A4 (en) 2022-12-14
WO2020190990A1 (en) 2020-09-24
AU2020240035A1 (en) 2021-10-07
US20220160703A1 (en) 2022-05-26
KR20220004025A (ko) 2022-01-11

Similar Documents

Publication Publication Date Title
CN105873440B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
AU2019293600A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
US20220401474A1 (en) Hdac6-activated macrophages, compositions, and uses thereof
EP3962493A2 (en) Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
AU2015360903B2 (en) Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
US20230114207A1 (en) The combination of cyclin dependent kinase 7 inhibitor and immunotherapy for treatment of cancer
JP7028765B2 (ja) ベンズアミドおよび活性化合物組成物および使用方法
WO2021263250A2 (en) Method of treating severe forms of pulmonary hypertension
JP2021512056A (ja) 細胞活性状態を調節することにより免疫細胞の炎症状態をインビボで変更すること
US20230114107A1 (en) Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2018085275A1 (en) Targeting lats1/2 and the hippo intracellular signaling pathway for cancer immunotherapy
AU2005304973A1 (en) Antibody induced cell membrane wounding
WO2023095929A1 (ja) 悪性腫瘍治療薬
Wang et al. Novel phenanthrene imidazoles as telomeric G-quadruplex ligands trigger potent immunogenic cell death in triple-negative breast cancer
US20200164034A1 (en) Methods for improving sex-dimorphic responses to targeted therapy in melanoma
JP2022525476A (ja) 腫瘍選択的併用療法
CN113382742A (zh) 工程化的鞭毛蛋白来源的组合物和用途
US20230405118A1 (en) Stat-activated macrophages, compositions, and uses thereof
WO2022192372A1 (en) Methods and compositions for tusc2 combination therapy with pdk1 inhibition
EP3054975A1 (en) Methods and compositions for regulatory t-cell ablation
CN113710660B (zh) Dot1l降解剂及其用途
CN112189013A (zh) 有机化合物
TW202241455A (zh) 使用akr1c3活化化合物與免疫檢查點抑制劑之組合療法
CA3146792A1 (en) Combination therapy for cancer treatment
US20240100021A1 (en) Combination Therapy Schedules to Treat Cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230314

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240523

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241017